Legend Biotech (LEGN)
(Delayed Data from NSDQ)
$41.39 USD
-3.23 (-7.24%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $41.59 +0.20 (0.48%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
LEGN 41.39 -3.23(-7.24%)
Will LEGN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for LEGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LEGN
Viatris to Report Q3 Earnings: What's in the Cards?
Gilead Science to Report Q3 Earnings: What's in the Cards?
LEGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade
Mortgage Rates Fall to a 12-Month Low
Pre-Markets in Red to Close an Eventful Week, Earnings Mixed
Other News for LEGN
RA Capital Management's Strategic Acquisition of GlycoMimetics Inc Shares
RA Capital Management, L.P. Acquires New Stake in Ensysce Biosciences Inc
Video: Tuesday's ETF Movers: MCHI, ICLN
RA Capital Management, L.P. Acquires New Stake in Eledon Pharmaceuticals Inc
Legend Biotech’s CARVYKTI Shows Promising Myeloma Results